GLP-1 drugs such as Ozempic and Wegovy have rapidly transformed the treatment of type 2 diabetes and obesity, but researchers are continuing to uncover their broader health effects. A new study, published in the journal Diabetes, Obesity and Metabolism, suggests these medications may also modestly reduce the risk of age-related vision loss.
The research found that older adults with obesity who used GLP-1 receptor agonists had a lower risk of developing age-related macular degeneration (AMD), the leading cause of irreversible vision loss among people over the age of 60 worldwide.
Large real-world study in Taiwan
The research team, led by Cheng-Hsien Hung of Chung Shan Medical University in Taiwan, analyzed health records from more than 157,000 patients. All participants were at least 60 years old, had obesity, and did not have diabetes, allowing the researchers to minimize the influence of blood sugar and diabetes-related factors.
Approximately half of the participants—nearly 79,000 people—were new users of GLP-1 receptor agonists, including liraglutide, semaglutide, and tirzepatide, prescribed for weight management. The remaining participants used other non-GLP-1 weight-loss medications and served as the comparison group during several years of follow-up.
Compared with patients taking other weight-loss medications, those receiving GLP-1 drugs had a significantly lower incidence of AMD. Overall, GLP-1 use was associated with an approximately 18% lower risk of developing AMD, with the reduction reaching nearly 30% for cases in which the specific AMD subtype was not identified in the insurance records.
Different effects across AMD subtypes
AMD occurs in two primary forms: nonexudative (dry) AMD, which is more common and typically progresses slowly, and exudative (wet) AMD, which is less common but tends to cause more rapid and severe vision loss.
The researchers found no clear association between GLP-1 use and the risk of developing wet AMD.
Although GLP-1 users showed a trend toward a lower risk of dry AMD, the finding did not reach statistical significance. The authors caution that the protective effect may differ between AMD subtypes or that the study was not large enough to detect smaller differences.
The duration of follow-up also differed between the two groups. GLP-1 users were followed for a median of approximately one year, while participants taking other weight-loss medications were followed for about 2.5 years. Because AMD develops slowly, these relatively short observation periods limit conclusions about long-term protection.
Possible mechanisms behind the eye benefits
Researchers are still investigating why GLP-1 receptor agonists might reduce the risk of AMD.
One proposed mechanism is that these medications exert direct neuroprotective effects on retinal cells by reducing inflammation. In particular, they may suppress activation of the NLRP3 inflammasome, an immune complex believed to contribute to retinal degeneration.
Another possibility is that the observed benefit is largely indirect. GLP-1 drugs generally produce greater weight loss than many older anti-obesity medications, reducing systemic inflammation and improving overall metabolic health, both of which may lower AMD risk.
Previous studies have linked higher body mass index (BMI) with an increased likelihood of AMD. One large analysis suggested that the risk rises by approximately 2% for every additional 1 kg/m² increase in BMI among overweight and obese adults, supporting the possibility that weight reduction itself contributes to better long-term eye health.
Cautious optimism and future research
The Taiwanese study builds on earlier research—much of it involving people with type 2 diabetes—that hinted GLP-1 receptor agonists might lower the risk of AMD. By focusing exclusively on adults without diabetes, the new findings strengthen the possibility that the effect extends beyond improvements in blood glucose control.
However, the researchers emphasize that the study is observational and cannot establish a direct cause-and-effect relationship. People prescribed GLP-1 medications may differ from those receiving other treatments in ways that are not fully captured in medical records, including lifestyle habits, healthcare access, or adherence to preventive care.
The authors call for prospective clinical studies that include detailed measurements of weight change, comprehensive eye examinations, retinal imaging, and longer follow-up periods. Additional laboratory research is also needed to determine whether GLP-1 drugs directly protect retinal tissue or whether any benefits are primarily a consequence of weight loss and improved metabolic health.
For now, experts stress that the findings are promising but preliminary. GLP-1 receptor agonists should not be prescribed solely to prevent age-related macular degeneration. Older adults should continue following well-established strategies for protecting their vision, including regular eye examinations, smoking cessation, a balanced diet, and careful management of cardiovascular risk factors.
